{"entity":{"id":"nct06678048","kind":"trial","name":"Arsenous Acid for Refractory Triple-Negative Breast Cancer","aka":[],"tldr":"A phase 2 trial in triple-negative breast cancer, run by Sun Yat-sen University, now recruiting.","summary":"Arsenous Acid for Refractory Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT06678048 by Sun Yat-sen University, with a registry enrolment figure of 12 participants, started 2024-10-23 and due to reach its primary completion in 2026-04-22. Interventions recorded: Arsenous Acid plus Chemotherapy. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: \"For TNBC patients with a programmed death-ligand 1 (PD-L1/22C3) positive result (combined positive score, CPS ) ≥10, eligibility requires prior treatment with chemotherapy combined with PD-1\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06678048","url":"https://clinicaltrials.gov/study/NCT06678048"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06678048","phase":"2","setting":"A Single-Arm, Two Stage, Phase II Study of Arsenous Acid Combined With Palliative Chemotherapy for Refractory Triple-Negative Breast Cancer","sponsor":"Sun Yat-sen University","enrolled":12,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06678048/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}